It’s only fair to share… Vaxine Pty Ltd company logo Vaxine’s promising new COVID-19 vaccine candidate A new multivalent COVID-19 vaccine developed by Australian company Vaxine to tackle the new virus variants could be game-changer in the fight against COVID-19 The world desperately needs a vaccine that blocks virus transmission and protects against all the …
Uprifosbuvir
It’s only fair to share… Uprifosbuvir MK 3682, IDX 21437 ウプリホスブビル; Formula C22H29ClN3O9P CAS 1496551-77-9 Mol weight 545.9071 уприфосбувир [Russian] [INN] أوبريفوسبوفير [Arabic] [INN] 乌磷布韦 [Chinese] [INN] propan-2-yl (2R)-2-[[[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Isopropyl (2R)-2-{[(R)-{[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-3-hydroxy-4-methyltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate IDX-21437, DB15206, SB18784, D10996, Q27281714 Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of Hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. It is currently in Phase III human clinical trials.[1][2][3] Uprifosbuvir is under investigation …
ARCT-021 (LUNAR-COV19)
It’s only fair to share… ARCT-021 (LUNAR-COV19) cas 2541451-24-3 A lipid-enabled and UnlockedNucleomonomer Agent modified RNA (LUNAR) of self-replicating RNA for vaccination against spike protein of SARS-CoV-2 (Arcturus) Self-replicating RNA vaccine Arcturus Therapeutics and Duke-NUS Medical School, Singapore OriginatorArcturus Therapeutics ClassCOVID-19 vaccines; RNA vaccines; Viral vaccines Mechanism of ActionImmunostimulants Orphan Drug StatusNo New Molecular EntityNo Available …
DAPAGLIFLOZIN
It’s only fair to share… DAPAGLIFLOZIN, BMS-512148 ダパグリフロジン; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Cas 461432-26-8 Molecular Formula: C21H25ClO6 Molecular Weight: 408.87 Dapagliflozin propandiol monohydrate; 960404-48-2 Molecular Weight 502.98 Formula C21H25ClO6•C3H8O2•H2O Bristol-Myers Squibb (Originator) AstraZeneca TYPE 2 DIABETES,SGLT-2 Inhibitors launched 2012, as forxiga in EU, FDA 2014, JAPAN PMDA 2014 Dapagliflozin propanediol monohydrate was first approved by European Medicine Agency (EMA) on November 12, …
IIBR-100
It’s only fair to share… IIBR-100 Brilife Recombinant vesicular stomatitis virus (rVSV) vaccine Israel Institute for Biological Research Hadassah Medical Center; Sheba Medical Center Hospital The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health …
ABDALA, CIGB-66
It’s only fair to share… ABDALA CIGB-66, is a COVID-19 vaccine Cuba says Abdala vaccine 92.28% effective against coronavirus The announcement came just days after the government said another homegrown vaccine, Soberana 2, has proved to be 62% effective with just two of its three doses. https://health.economictimes.indiatimes.com/news/industry/cuba-says-abdala-vaccine-92-28-effective-against-coronavirus/83735386 June 22, 2021, 10:03 IST Havana: Cuba said on Monday that its …
QazCovid-in
It’s only fair to share… QazCovid-in QazCovid-in Vaccine Phase I/II/III The QazCovid-in vaccine is an inactivated vaccine. Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) and/or by inactivation using a chemical reagent (such as beta-propiolactone or formaldehyde). Upon vaccination, this allows the body to generate a …
COVIran Barakat
It’s only fair to share… COVIran Barakat Vaccine description Target SARS-CoV-2 Vaccine type Inactivated Clinical data Routes of administration Intramuscular ATC code None Legal status Legal status Emergency use authorization: IRN Full and Emergency Authorizations: List of COVIran Barakat COVID-19 vaccine authorizations COVIran Barakat COVIran Barakat, is an inactivated virus vaccine developed by Shifa Pharmed Industrial Co in …
Convidicea (Ad5-nCoV)
It’s only fair to share… AD5-nCOV A vial of Convidecia vaccine Vaccine description Target SARS-CoV-2 Vaccine type Viral vector Clinical data Trade names Convidecia Routes of administration Intramuscular, Intranasal ATC code None Legal status Legal status Full and Emergency authorizations Identifiers DrugBank DB15655 Convidicea (Ad5-nCoV) Recombinant vaccine (adenovirus type 5 vector) Recombinant Novel Coronavirus Vaccine (Adenovirus …
EpiVacCorona
It’s only fair to share… Origin of EpiVacCorona antigenes MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDLSKQLQQSMSSADSTQA. “Carrier protein sequence”. EpiVacCorona Federal Budgetary Research Institution State Research Center of Virology and Biotechnology peptide, russia PATENT https://www.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2743594&TypeFile=html RU 2 743 594 RU 2 743 593 RU 2 743 595 RU 2 738 081 Science (Washington, DC, United States) (2021), 372(6538), 116-117. EpiVacCorona (Russian: ЭпиВакКорона, tr. EpiVakKorona) is a peptide-based vaccine against COVID-19 developed by the VECTOR center of …